Drug intelligence / Profile preview

T-4008-1

Development stage: Unknown
Lead developer: Chenland Nutritionals
Modality: Small Molecules
Administration: Oral

Overview

T-4008-1 is a small molecule triple reuptake inhibitor (SNDRI) developed by EasyMind (Beijing EasyMind Technology) for the treatment of major depressive disorder (MDD). By simultaneously inhibiting the reuptake of serotonin, norepinephrine, and dopamine, T-4008-1 aims to provide a more comprehensive therapeutic effect and a faster onset of action than conventional antidepressants like SSRIs or SNRIs. The compound is designed to address the limitations of current therapies, such as low remission rates and delayed clinical response. It is currently undergoing Phase 1 clinical trials in China.

Targets

DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on T-4008-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-4008-1.

Explore the full profile